HealthCare CELLTRION
Rituximab biosimilar

Targets the CD20 antigen expressed on the
surface of pre-B and mature B-lymphocytes.
Upon binding to CD20, rituximab mediates
B-cell lysis.

Trastuzumab BIOSIMILAR

Binds with high affinity and specificity to
the extracellular domain of HER2.